|
Market Closed -
Nasdaq
16:00:00 2026-08-18 EDT
|
5-day change | 1st Jan Change | ||
| 4.090 USD | +0.74% |
|
+0.25% | +154.04% |
| 08-17 | B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating | MT |
| 08-13 | MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MACROGENICS, INC. | Bio Therapeutic Drugs | +0.74% | +0.25% | +154.04% | +158.86% | -82.86% | 259M |  |  | |
- Stock Market
- Stocks
- MGNX Stock
- Charts MacroGenics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
